Sihuan Pharmaceutical Holdings Group Ltd. (DE:TEL1)
FRANKFURT:TEL1
TEL1 Stock Chart & Stats
€0.16
-€0.01(-12.66%)
At close: 4:00 PM EST
€0.16
-€0.01(-12.66%)
Day’s Range― - ―
52-Week Range€0.10 - €0.21
Previous CloseN/A
Volume0.00
Average Volume (3M)1.21K
Market Cap
€953.77M
Enterprise Value€4.11B
Total Cash (Recent Filing)€4.10B
Total Debt (Recent Filing)€1.01B
Price to Earnings (P/E)37.7
Beta0.28
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding9,329,999,000
10 Day Avg. Volume1,416
30 Day Avg. Volume1,205
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.19Price Target Upside20.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€391.78M
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA 21.6% revenue rebound and return to positive net income in 2025 signal restored commercial traction and product demand across hospital channels. Sustained top-line recovery supports cash generation, funds R&D and commercial investment, and improves the probability of durable earnings improvement over coming quarters.
High Gross MarginsConsistently high gross margins (~65–70%) provide structural earnings leverage, giving the company scope to absorb pricing pressure and support SG&A or R&D spending without immediate margin collapse. This margin profile is a durable buffer that can preserve profitability through cyclical revenue swings if operational execution holds.
Low Leverage / Strong Balance SheetDebt-to-equity improving to about 0.16 and a sizable equity base means low financial leverage and a meaningful cushion against shocks. This enhances flexibility for capex, R&D or selective M&A, reduces refinancing risk and supports resilience across business cycles over the medium term.
Bears Say
Weak Cash GenerationOperating cash flow dipping negative while free cash flow was deeply negative in 2025—despite reported net income—signals weak cash conversion and raises earnings-quality concerns. Persistent FCF inconsistency limits financial flexibility, could constrain reinvestment or dividends, and increases reliance on external funding if not corrected.
Earnings VolatilityMulti-year profit swings (large loss in 2022, negative margins in 2024 and recovery in 2025) indicate execution or cyclical risk. Low ROE (~3% in 2025) shows limited shareholder returns. This volatility undermines predictability for planning, capital allocation and long-term investor confidence absent sustained improvement.
Regulatory & Reimbursement ExposureRevenue is concentrated in hospital-channel drug sales and explicitly depends on pricing, tendering and reimbursement policies in China. Persistent regulatory and reimbursement risk can materially affect volumes, pricing and margins over time, making revenue and profit durability sensitive to policy shifts beyond the company’s control.
Sihuan Pharmaceutical Holdings Group News
TEL1 FAQ
What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?
Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was €0.10 and its highest was €0.21 in the past 12 months.
What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?
Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is €953.77M.
When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?
Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 75 days.
How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?
Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Mar 31, 2026. The company reported <€0.001 earnings per share for the quarter, beating the consensus estimate of N/A by <€0.001.
Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?
According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued.
Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?
Sihuan Pharmaceutical Holdings Group Ltd. does not currently pay dividends.
What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?
Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?
Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.
What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?
Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of <€0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.721%.
Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?
Currently, no hedge funds are holding shares in DE:TEL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sihuan Pharmaceutical Holdings Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
229.16%
12-Months-Change
Fundamentals
Return on Equity
3.51%
Trailing 12-Months
Asset Growth
15.37%
Trailing 12-Months
Company Description
Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Holdings Group Ltd. functions as an investment holding company, primarily dedicated to the research, development, manufacturing, marketing, and distribution of pharmaceutical products across the People's Republic of China. Its drug portfolio encompasses a range of therapeutic areas, including oncology, metabolic disorders, and digestive system ailments. The company also diversifies its operations through investments in and sales of medical aesthetic products, the production of medical devices, property investments, undertaking medical construction initiatives, and preparing for new pharmaceutical manufacturing projects. Additionally, it delivers various services, such as informational support, general hospital services, hospital management, biotechnology promotion, and research and development in medical aesthetics. Founded in 2001, the firm is headquartered in Wanchai, Hong Kong.
TEL1 Stock 12 Month Forecast
Average Price Target
€0.19
▲(20.23% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---